Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-β plaques

J-Y Kim1,2, DH Kim1, JH Kim1, D Lee1, HB Jeon1, S-J Kwon1, SM Kim3, YJ Yoo4, EH Lee2, SJ Choi1, SW Seo5, Ji Lee6, DL Na5, YS Yang1, W Oh1 and JW Chang*1

Presently, co-culture of human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) with BV2 microglia under amyloid-β(42) (Aβ42) exposure induced a reduction of Aβ42 in the medium as well as an overexpression of the Aβ-degrading enzyme neprilysin (NEP) in microglia. Cytokine array examinations of co-cultured media revealed elevated release of soluble intracellular adhesion molecule-1 (sICAM-1) from hUCB-MSCs. Administration of human recombinant ICAM-1 in BV2 cells and wild-type mice brains induced NEP expression in time- and dose-dependent manners. In co-culturing with BV2 cells under Aβ42 exposure, knockdown of ICAM-1 expression on hUCB-MSCs by small interfering RNA (siRNA) abolished the induction of NEP in BV2 cells as well as reduction of added Aβ42 in the co-cultured media. By contrast, siRNA-mediated inhibition of the sICAM-1 receptor, lymphocyte function-associated antigen-1 (LFA-1), on BV2 cells reduced NEP expression by ICAM-1 exposure. When hUCB-MSCs were transplanted into the hippocampus of a 10-month-old transgenic mouse model of Alzheimer’s disease for 10, 20, or 40 days, NEP expression was increased in the mice brains. Moreover, Aβ42 plaques in the hippocampus and other regions were decreased by active migration of hUCB-MSCs toward Aβ deposits. These data suggest that hUCB-MSC-derived sICAM-1 decreases Aβ plaques by inducing NEP expression in microglia through the sICAM-1/LFA-1 signaling pathway.

Cell Death and Differentiation (2012) 19, 680–691; doi:10.1038/cdd.2011.140; published online 21 October 2011

Alzheimer’s disease (AD) is an irreversible neurodegenerative disease that is accompanied by amyloid-β (Aβ) accumulation, tau aggregation, and chronic inflammation.1 Clinical trials evaluating new drugs for AD patients have proved disappointing. For example, phase-III clinical trials of Dimebon, a spotlighted candidate drug for AD, failed.2 Therefore, the limitations of conventional drugs call for a paradigm shift in AD research.

In this light, stem cell therapeutics for incurable diseases is relevant. Stem cells have the ability to self-renew and differentiate into tissues.3 Although human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) are allogenic stem cells, their transplantation does not induce immunological problems in hosts because these cells do not express major histocompatibility complex class-II molecules and T-cell co-stimulatory factors.4–6 In addition, collection of hUCB-MSCs is less invasive and they are easily obtained from cord blood after birth.

Recently, many groups have reported that stem cells have regenerative as well as paracrine effects. The paracrine roles of stem cells have been shown in that stem cell-derived soluble factors can modulate apoptosis, differentiation, proliferation, and inflammation in damaged tissue.7–9 In particular, our group has shown that galectin-3, which is secreted by hUCB-MSCs, reduces Aβ neurotoxicity in rat primary neurons.10 Furthermore, our group reported that transplantation of hUCB-MSCs improved spatial memory deficits and reduced Aβ deposits in a transgenic mouse model of AD.11,12 Although toxic Aβ deposits were reduced significantly in the hUCB-MSC-transplanted mice, the molecular mechanisms are poorly understood.

The present study sought to clarify the mechanisms involved. Transplantation of hUCB-MSCs in AD transgenic mice induced the expression of the Aβ-degrading enzyme neprilysin (NEP) in microglia through a paracrine mechanism. Analysis of the proteins secreted by hUCB-MSCs revealed that soluble intracellular adhesion molecule-1 (sICAM-1) is released from hUCB-MSCs, which, in turn, induces NEP in microglia for Aβ clearance.
Co-culture of hUCB-MSCs induces NEP expression in microglia. As transplantation of hUCB-MSCs reduces Aβ deposits in vivo, we tested whether co-culture with hUCB-MSCs in a Transwell chamber could affect the expression of Aβ metabolic enzymes, including NEP, in rat primary neuronal cultures. NEP is an Aβ-degrading enzyme that is emerging as a therapeutic target in AD. After co-culture with hUCB-MSCs for 24 h in the presence or absence of 10 μM Aβ42, NEP expression in rat primary neuronal cultures was analyzed by reverse transcription-PCR (RT-PCR) and western blot analysis (Figure 1). Co-culture with hUCB-MSCs induced NEP expression in cultured rat primary neuronal culture in the absence and presence of Aβ42 (Figure 1a). As the rat primary neuronal cultures contained a mixture of neuronal and glial cells, we performed a colocalization analysis of NEP-positive cells and microglia (Figure 1b), and neurons (Supplementary Figure S1a). Co-culture with hUCB-MSCs in the presence of Aβ42 demonstrated colocalization of microglia and NEP-expressing cells (red color) by double staining using...
antibodies against CD11b, a marker of microglia (green), and NEP (Figure 1b). Although staining in some microtubule-associated protein-2 (MAP2)-positive cells (neurons) merged with NEP-expressing cells, the majority of NEP-positive cells were microglia. Moreover, we tested upregulation of NEP in mouse microglial BV2 cells by co-culturing them with hUCB-MSCs isolated from six different donors. Western blot analysis revealed that co-culture of six hUCB-MSCs induced an upregulation of NEP in BV2 cells (*P<0.05 versus BV2 cells only; Figure 1c). As co-culture with hUCB-MSCs induced NEP expression in BV2 cells, we measured the concentration of added Aβ42 in the co-cultured media to determine whether endogenous NEP was induced in microglia or whether neurons degraded Aβ42 in the media. The level of Aβ42 in the media was compared when hUCB-MSCs were co-cultured with BV2 cells or human neuroblastoma SH-SY5Y cells (Supplementary Figure S1b). Significant reductions in Aβ42 concentration were observed in the media of BV2 cells co-cultured with hUCB-MSCs in the presence of 10 μM Aβ42, as compared with the media of SH-SY5Y co-cultured with the same concentration of Aβ42 (*P<0.05 versus SH-SY5Y alone with Aβ42 (n=3 per group); and **P<0.05 versus BV2 alone with Aβ42 (n=3 per group)). These results may have been due to induction of NEP in the majority of microglia. To determine whether reduction of Aβ42 in the media was mediated by NEP in microglia, two different small interfering RNAs (siRNAs) for NEP were transfected into BV2 cells, which were then co-cultured with hUCB-MSCs in the presence of 10 μM Aβ42. The concentration of added Aβ42 was reduced significantly in the media of BV2 cells co-cultured with hUCB-MSCs or control siRNA-treated hUCB-MSCs, as compared with BV2 cells cultured alone in the same amount of Aβ42. By contrast, pretreatment of BV2 cells with two different NEP siRNAs abolished this reduction of Aβ42 in the media upon co-culture with hUCB-MSCs (Figure 1d). The effect of NEP knockdown was evaluated by western blot analysis (Figure 1e). The data indicate that hUCB-MSCs reduced Aβ42 through induction of NEP expression in microglia.

Identification of sICAM-1 as a paracrine factor released by hUCB-MSCs for NEP induction. In Transwell chamber experiments, cells cannot pass through the Transwell membrane because of the restrictive pore size (1 μm). Thus, secreted factors released from hUCB-MSCs can act on microglia in the co-culture system. To identify the paracrine factors, cytokine array were performed by using the following conditioned media: hUCB-MSCs or BV2 cells alone; Aβ42-treated hUCB-MSCs or BV2 cells; and BV2 cells co-cultured with hUCB-MSCs in the presence or absence of Aβ42 (Figure 2a). Densitometric analysis revealed that interleukin-8 (IL-8), IL-6, growth-regulated oncogene-α (GRO-α), and ICAM-1 cytokines were markedly increased in the media of BV2 cells co-cultured with hUCB-MSCs in both the presence and in the absence of Aβ42 (Figure 2b, n=3 per group; *P<0.05 versus MSC alone). Next, we examined which co-cultured cells secreted the identified cytokines. After co-culturing BV2 cells with hUCB-MSCs, either cell type was harvested separately and the expression of each individual cytokine was analyzed by RT-PCR. IL-8, IL-6, GRO-α, and ICAM-1 were overexpressed in co-cultured hUCB-MSCs but not in BV2 cells (Figures 2c and d). In particular, ICAM-1 levels were increased by co-culturing BV2 cells with hUCB-MSCs obtained from two individuals (Figure 2d). These data demonstrate that increased levels of ICAM-1 were released from hUCB-MSCs by co-culturing with BV2 cells.

Among these cytokines, only ICAM-1 treatment induced the expression of NEP in BV2 cells in time- and dose-dependent manners (Figure 3a, *P<0.05 versus without recombinant ICAM-1; n=3 per group). As NEP expression was upregulated by ICAM-1 in the absence and presence of Aβ42 (Figure 3a), a dose of 500 or 1000 ng/kg of human ICAM-1 in a day induced an upregulation of NEP in BV2 cells (*P<0.05 versus control ICAM-1 alone; Figure 3b). Densitometric analysis revealed that ICAM-1 treatment induced NEP expression in BV2 cells in time- and dose-dependent manners (Figure 3a, *P<0.05 versus control ICAM-1 alone; Figure 3b). Densitometric analysis revealed that ICAM-1 treatment induced NEP expression in BV2 cells in time- and dose-dependent manners (Figure 3a, *P<0.05 versus control ICAM-1 alone; Figure 3b). Densitometric analysis revealed that ICAM-1 treatment induced NEP expression in BV2 cells in time- and dose-dependent manners (Figure 3a, *P<0.05 versus control ICAM-1 alone; Figure 3b). Densitometric analysis revealed that ICAM-1 treatment induced NEP expression in BV2 cells in time- and dose-dependent manners (Figure 3a, *P<0.05 versus control ICAM-1 alone; Figure 3b). Densitometric analysis revealed that ICAM-1 treatment induced NEP expression in BV2 cells in time- and dose-dependent manners (Figure 3a, *P<0.05 versus control ICAM-1 alone; Figure 3b). Densitometric analysis revealed that ICAM-1 treatment induced NEP expression in BV2 cells in time- and dose-dependent manners (Figure 3a, *P<0.05 versus control ICAM-1 alone; Figure 3b). Densitometric analysis revealed that ICAM-1 treatment induced NEP expression in BV2 cells in time- and dose-dependent manners (Figure 3a, *P<0.05 versus control ICAM-1 alone; Figure 3b).

Figure 2 Cytokine analyses identify four proteins that are upregulated in the media of BV2 cells co-cultured with hUCB-MSCs. (a) Medium was collected from BV2 cells and hUCB-MSCs alone; BV2 cells co-cultured with hUCB-MSCs in the presence and absence of Aβ42; and BV2 cells or hUCB-MSCs alone in the presence of Aβ42. Cytokine analysis was performed according to a recommended protocol. The boxed area indicates upregulation of four proteins in the medium from BV2 cells co-cultured with hUCB-MSCs in the presence or absence of Aβ42. A typical result of densitometric analysis obtained from three independent experiments (n=3 per group; *P<0.05 versus MSC alone). (b) To determine which cells secreted GRO-α, IL-6, IL-8, and ICAM-1 when co-cultured in the Transwell system, BV2 cells and hUCB-MSCs were co-cultured and then analyzed by RT-PCR using a specific primer for human GRO-α, IL-6, and IL-8. (d) In the same experiment as in panel c, BV2 cells were co-cultured with two different hUCB-MSCs to analyze ICAM-1 expression in RT-PCR using a primer for human ICAM-1.
recombinant ICAM-1 or phosphate-buffered saline (PBS) was administered to the hippocampus of 10-month-old littermate mice for 7 days. After 7 days, the brain tissue was analyzed by western blot analyses. Densitometric analyses indicated an increase of NEP in three independent experiments (*P < 0.05). (b) Dose-dependent human recombinant ICAM-1 (500 and 1000 ng/kg) was injected bilaterally into the hippocampus of B6C3 mice for 7 days. As control, PBS was injected into both hippocampi. The collected brains were analyzed by western blot analysis using an anti-NEP antibody. NEP levels were upregulated at 1000 ng/kg when analyzed by densitometric analysis (n = 4 per group; *P < 0.05 versus PBS control). (c) To knock down ICAM-1 in hUCB-MSCs, hUCB-MSCs were pretreated with an siRNA control (siCONT) or siRNA (A) and siRNA (B) of ICAM-1 for 14 h, and then these cells were co-cultured with BV2 cells for an additional 24 h in the presence of Aβ42. The levels of sICAM-1 in each media were measured by ELISA (*P < 0.05; n = 3 per group). (d) BV2 cells were harvested from the above conditions and analyzed by western blot analysis using an anti-NEP antibody. (e) To determine whether the reduced sICAM-1 secretion affected the ability of Aβ42 reduction by hUCB-MSCs, the Aβ42 levels in the media were measured by Aβ42 ELISA. (f) To knock down LFA-1, BV2 cells were pretreated for 14 h with two different siRNAs for LFA-1, siRNA LFA-1 A and LFA-1 B, and then these cells were exposed to recombinant ICAM-1 (20 ng/ml) for 24 h. Knockdown of LFA-1 was confirmed by RT-PCR. Reduced NEP expression by siRNAs of LFA-1 was confirmed by western blot analysis using an anti-NEP antibody. Densitometric analysis of NEP was performed in three independent experiments (*P < 0.05; n = 3 versus siCONT-treated BV2 with ICAM-1).

Figure 3  Identification of hUCB-MSC-derived sICAM-1 as an inducer of NEP expression in microglia. (a) BV2 cells were treated with human recombinant ICAM-1 in a dose- (5, 10, and 50 ng/ml) and time-dependent (12, 24, 36, or 48 h) manner. Each cell lysate was analyzed with an anti-NEP antibody by western blot analyses. Densitometric analyses indicated an increase of NEP in three independent experiments (*P < 0.05). (b) Dose-dependent human recombinant ICAM-1 (500 and 1000 ng/kg) was injected bilaterally into the hippocampus of B6C3 mice for 7 days. As control, PBS was injected into both hippocampi. The collected brains were analyzed by western blot analysis using an anti-NEP antibody. NEP levels were upregulated at 1000 ng/kg when analyzed by densitometric analysis (n = 4 per group; *P < 0.05 versus PBS control). (c) To knock down ICAM-1 in hUCB-MSCs, hUCB-MSCs were pretreated with an siRNA control (siCONT) or siRNA (A) and siRNA (B) of ICAM-1 for 14 h, and then these cells were co-cultured with BV2 cells for an additional 24 h in the presence of Aβ42. The levels of sICAM-1 in each media were measured by ELISA (*P < 0.05; n = 3 per group). (d) BV2 cells were harvested from the above conditions and analyzed by western blot analysis using an anti-NEP antibody. (e) To determine whether the reduced sICAM-1 secretion affected the ability of Aβ42 reduction by hUCB-MSCs, the Aβ42 levels in the media were measured by Aβ42 ELISA. (f) To knock down LFA-1, BV2 cells were pretreated for 14 h with two different siRNAs for LFA-1, siRNA LFA-1 A and LFA-1 B, and then these cells were exposed to recombinant ICAM-1 (20 ng/ml) for 24 h. Knockdown of LFA-1 was confirmed by RT-PCR. Reduced NEP expression by siRNAs of LFA-1 was confirmed by western blot analysis using an anti-NEP antibody. Densitometric analysis of NEP was performed in three independent experiments (*P < 0.05; n = 3 versus siCONT-treated BV2 with ICAM-1).
To investigate the signal pathway of ICAM-1-induced NEP expression on microglia, we tested whether ICAM-1 could interact with its known receptor. As lymphocyte function-associated antigen-1 (LFA-1), integrin-β2 has been proposed as the ICAM-1 receptor in lymphocytes, we tested whether knockdown of LFA-1 expression in BV2 cells by two different specific siRNAs of LFA-1 could abolish NEP expression by ICAM-1 treatment. When LFA-1 expression was reduced by these siRNAs, ICAM-1-induced NEP expression was also significantly downregulated (Figure 3f). Knockdown of LFA-1 on BV2 was confirmed by RT-PCR and immunostaining (Supplementary Figure S2). These data indicated that ICAM-1-induced NEP expression could be regulated by the integrin-β2 LFA-1-mediated signaling pathway.

Knockdown of ICAM-1 reduces the neuroprotective effects of hUCB-MSCs against Aβ42 neurotoxicity. To determine the role of sICAM-1 in the neuroprotective effects of hUCB-MSCs in Aβ42-exposed rat primary neuronal cultures, we compared the neuroprotective effects of hUCB-MSCs in the absence and presence of two different ICAM-1 siRNAs. Reduced levels of sICAM-1 in the media were confirmed by ELISA (Figure 4a). Reduction of Aβ42 concentration was observed in rat primary neuronal cultures after co-culturing with control siRNA-treated hUCB-MSCs, as compared with co-culture with ICAM-1 siRNA-treated hUCB-MSCs (Figure 4b) (*P<0.05 versus siRNA control treated hUCB-MSC; n = 3 per group). Although hUCB-MSCs alone protected Aβ42-exposed, MAP2-positive rat primary neurons, ICAM-1 siRNA-treated hUCB-MSCs did not protect neurons from death (Figures 4c and d). The percentage of surviving neurons was analyzed by counting the number of MAP2-positive cells in each condition (n = 3 per group; *P<0.05). These data indicate that the neuroprotective effects of hUCB-MSCs were mediated by the NEP expression induced by sICAM-1.

Transplantation of hUCB-MSCs induces NEP expression in vivo. To evaluate the induction of NEP expression by hUCB-MSCs in vivo, we performed bilateral transplantation of hUCB-MSCs (2 × 10^4 cells per head) into the hippocampal tissues of 10-month-old APP/PS1 double-transgenic mice in a time-dependent manner. As control, human skin fibroblast Hs68 cells were administered (Figure 5a). To check whether injection was performed in accurate positions in the hippocampus, brain tissues at 10 days were stained by a human-specific anti-β2-microglobulin (brown). The majority of transplanted hUCB-MSCs were stained in the needle track of the hippocampus at 10 days (Figure 5b). Although these antibodies detected human chondrocytes, they did not detect
b2-microglobulin in mouse liver and muscle (Supplementary Figure S3). To analyze the survival of transplanted hUCB-MSCs, we double stained using an antibody for human-specific anti-human nuclei (green) and human b2-microglobulin (red) at 10, 20, and 40 days. The stained hUCB-MSCs were clearly detected, and the red and blue cells were completely merged in images collected at 10 and 20 days. However, hUCB-MSCs were significantly reduced at 40 days (Figure 5c) in all brain areas. Before transplantation of the hUCB-MSCs, we examined the levels of NEP expression in the transgenic mice at various ages. NEP expression was significantly reduced at 12 and 18 months (Figure 6a, *P<0.05 versus 6-month-old transgenic mice; n = 4 per group). However, Aβ42 accumulation was noted. After
transplantation of hUCB-MSCs and Hs68, mice were killed at 10, 20, and 40 days to perform western blot analyses and immunohistochemistry (IHC). As in our in vitro data, NEP expression was increased in a time-dependent manner by transplantation of hUCB-MSCs as compared with the Hs68-injected group (Figure 6b). In densitometric analysis, NEP expression was significantly increased by an average of 20% and 38% at 20 and 40 days, respectively, after hUCB-MSC transplantation, as compared with 10 days in the Hs68 controls (Figure 6b, *P < 0.05; n = 4 per group). Another Aβ-degrading enzyme, insulin-degrading enzyme (IDE), was also applied to the same tissue. IDE expression levels were not changed by hUCB-MSCs (Figure 6b).

To analyze the colocalization of microglia and NEP expression in the hippocampal region of 20-day-old mice, double staining was performed using antibodies against NEP and CD11b in coronal brain sections (Figure 6c). It was difficult to observe any colocalization of microglia and NEP expression in the Hs68-injected group (n = 4). However, NEP expression was clearly noted in the microglia of the group transplanted with hUCB-MSCs (n = 4). Colocalization of neurons and NEP expression was also examined in tissues. A few MAP2-positive neurons colocalized with NEP-expressing cells, as compared with CD11b-positive microglia (Supplementary Figure S4). These data indicate that transplanted hUCB-MSCs induced NEP expression in the microglia of AD-transgenic mice.

Transplantation of hUCB-MSCs reduces Aβ plaques in vivo. To confirm whether the number of Aβ plaques was affected by transplantation of hUCB-MSCs, thioflavin-S...
staining of Aβ plaques was performed in each of the tested tissues from 40-day-old mice, although the majority of hUCB-MSCs had disappeared (Figure 7A). The boxed area in the images was magnified to visualize Aβ plaques in each coronal section. Aβ plaques in the hippocampal (a and b) and cortical regions (c and d) from Hs68-injected and hUCB-MSC-injected groups (Figure 7A) were magnified. Quantitative image analysis of the area occupied by the Aβ plaques showed statistically significant reductions (Figure 7B, *P<0.05; n=4 per group) in hUCB-MSC-transplanted mice, as compared with Hs68-injected APP/PS1 mice. Additionally, reduced Aβ42 monomers were also confirmed by western blot analysis using an anti-Aβ42 antibody (Figure 7C, *P<0.05 versus the Hs68-injected group; n=4 per group). Furthermore, ELISA analyses of the same brain extracts revealed reduced Aβ42 level in the hUCB-MSC-injected group (*P<0.05 versus the Hs68-injected group; n=4).

**Figure 7**  Transplantation of hUCB-MSCs reduces Aβ plaques in APP/PS1 mice. (A) Brain sections from the Hs68 and hUCB-MSC-injected groups that survived for 40 days were stained with thioflavin-S to visualize Aβ plaques. The yellowish dots indicate Aβ plaques. Images a and b indicate the enlarged hippocampal region, and images c and d show the magnified cortical region. (B) Aβ plaques were measured by image analysis (n = 4 per group; *P<0.05 versus the Hs68-injected group). (C) The levels of Aβ42 were detected in brain tissues, including the littermate, the Hs68- and hUCB-MSC-injected groups, by western blot analysis using an anti-Aβ42 antibody. Litter indicates littermate of APP-PS1 mice. Densitometric analysis revealed decreased Aβ42 level in the hUCB-MSC-injected group (*P<0.05 versus the Hs68-injected group; n=4). Detergent-soluble and insoluble Aβ40 (D) or Aβ42 (E) were analyzed by specific ELISA (*P<0.05 versus the Hs68-injected group; n = 4 per group). Preparation of insoluble and soluble Aβ was performed as described by Nikolic et al.29
that the levels of both detergent-soluble and -insoluble Aβ/40 and Aβ/42 were reduced significantly in the hUCB-MSC injected groups (Figures 7D and E, *P < 0.05; n = 4 per group). As the results of thioflavin-S staining correlated with western blot analysis using anti-Aβ/42 antibody and ELISA, these data indicate that hUCB-MSC transplantation decreased Aβ plaques through NEP expression of microglia.

Detection of hUCB-MSCs expressing ICAM-1 in other brain areas. Although hUCB-MSCs were transplanted only in the hippocampus, Aβ plaques in remote cortices from the hippocampus were reduced markedly (Figure 7). From this phenomenon, we tested whether hUCB-MSCs could migrate to other brain areas such as the cortex in the frontal lobe. Brain tissues were collected from the frontal lobe of hUCB-MSC-transplanted AD mice at 20 days and analyzed by using anti-human nuclei (green) and ICAM-1 (red) antibodies to analyze the colocalization of ICAM-1 and hUCB-MSC. Interestingly, hUCB-MSCs expressing ICAM-1 were detected in other brain areas at 20 days in AD mice (Figures 8A–E). hUCB-MSCs expressing ICAM-1 (orange cells in the merged image) were detected in the neocortex, hypothalamus, amygdale, and striatum. Each region (a–e) is marked in Figure 8F. In our previous reports,17–19 hUCB-MSC migrated toward the cell secreting the inflammatory cytokine IL-8 in vitro and in vivo. Microglia that secrete inflammatory cytokines are usually localized near Aβ plaques in AD.20–22 Based on these findings, migrating hUCB-MSCs (green) were often observed near Aβ deposits (red) in brain tissues (Figure 8G). This migration toward Aβ plaques was too robust, because hUCB-MSCs injected into the cerebrospinal fluid (CSF) through the cisterna magna also migrated to the brain parenchyma. For example, under the subarachnoid space (yellow dashed line), part of the circulation route of the CSF, migrating hUCB-MSCs were detected near Aβ deposits on the edge of cortex (box h in Figure 8F) (Figure 8H). Surprisingly, when hUCB-MSCs were inoculated in the hippocampus or the CSF in normal mice, hUCB-MSC migration was not found in other brain areas (data not shown). These data indicated that Aβ plaques located remotely from injection sites could be removed by migration of hUCB-MSCs toward Aβ deposits.

Discussion

In stem cell therapy, several trials using AD models have been conducted by using transplantation of rat or mouse neural stem cells.23–25 In these trials, Aβ, IDE, and the tau status were not altered by transplantation of neural stem cells. The majority of these studies have demonstrated that transplantation of neural stem cells ameliorates AD-associated behavioral deficits. Here, for the first time, we demonstrate removal of Aβ through hUCB-MSC-derived sICAM-1 by induction of endogenous NEP in a mouse model of AD.

The metabolism of Aβ is a major target for new drug development. In particular, NEP is an emerging target for Aβ-targeted drugs, because decreased Aβ clearance in AD patients was reported.26 Therefore, recovery of NEP expression in patients with AD may be a possible strategy for AD therapy.

In this study, expression of the Aβ cleavage enzyme, NEP, was induced by co-culturing hUCB-MSCs in microglia cells. NEP induction in the media was able to degrade Aβ/42 because knockdown of NEP in BV cells abolished Aβ removal by hUCB-MSC co-culture (Figure 1). Moreover, transplantation of hUCB-MSCs at 10, 20, and 40 days in the bilateral hippocampus also induced a time-dependent NEP expression in AD-transgenic mice (Figure 6). These data support the idea that reduction of Aβ plaques by hUCB-MSCs is due to induction of NEP in mouse brain. In this study, we examined how hUCB-MSCs can induce NEP in microglia by using a Transwell system. From cytokine analyses of the conditioned media, we identified release of ICAM-1 by hUCB-MSCs (Figure 2) and found that recombinant ICAM-1 induced NEP expression in vitro and in vivo (Figure 3). In addition, knockdown of ICAM-1 expression in hUCB-MSCs abolished the reduction of Aβ/42 and NEP expression in BV2 cells (Figure 3). Consequently, the neuroprotective effects of hUCB-MSCs were inhibited significantly in rat primary cultures with inhibition of ICAM-1 expression in hUCB-MSCs (Figure 4). These data are consistent with the view that sICAM-1 from hUCB-MSCs induces the expression of NEP in microglia, which then remove Aβ plaques (Figure 9).

ICAM-1 is a cell-surface molecule that is expressed by multiple types of cells, including epithelial cells, leukocytes, endothelial cells, and fibroblasts. It is a member of the immunoglobulin superfamily of adhesion molecules that are involved in cell–cell and cell–matrix interactions. Although the predominant function of ICAM-1 is cell adhesion, soluble and circulating forms of ICAM-1 are detected in body fluids, including serum and the CSF.27 Presently, ICAM-1 expression in naïve hUCB-MSCs was low because expression of ICAM-1 mRNA or sICAM-1 in media was detected only in the media of hUCB-MSCs co-cultured with BV2 cells (Figure 2). LFA-1 is a receptor for ICAM-1 in lymphocytes.14,15 We confirmed that knockdown of LFA-1 expression in BV2 cells abolished ICAM-1-induced NEP expression in these cells (Figure 3f). Especially, ICAM-1 stimulates downstream extracellular signal-regulated kinase (Erk)-1,2 activation in T-cell receptor activation through the LFA-1 signaling pathway.28 In this study, we examined several major kinases during ICAM-1 exposure in BV2 cells. Among these, c-Jun N-terminal kinase (JNK) and Erk-1,2 were activated in a time-dependent manner. Inhibition of these two kinases by specific inhibitors did not affect NEP expression by ICAM-1 in BV2 cells (data not shown). Although LFA-1/ICAM-1 interacts in BV2 cells, such as occurs in lymphocytes, the downstream signaling pathway should be investigated using phospho-histone assays to find novel pathways. In conclusion, NEP induction in microglia by ICAM-1 must be mediated by the LFA-1, integrin-β2 pathway.

In this study, we observed an additional role of hUCB-MSC-derived sICAM-1 in microglial function. In a previous report, Nikolic et al.29 reported that administration of hUCB-mono-nuclear cells (MNCs) decreases Aβ plaques by disrupting CD40/CD40L activity in microglia. Interestingly, Tan et al. reported that CD40 ligation promotes proinflammatory activation of microglia and reduces microglial phagocytosis of
By contrast, interruption of CD40/CD40L rescues Aβ deposition and tau hyper-phosphorylation in an AD animal model. Based on these reports, we can conclude that reduction of CD40 expression by hUCB-MNC administration must be involved in a therapeutic effect in the AD model. As reported previously, CD40 expression was presently also downregulated by hUCB-MSC transplantation, compared with the control groups (Supplementary Figure S5a). Interestingly, we presently observed that exposure to recombinant ICAM-1 reduced CD40 expression in BV2 cells in vitro. By contrast, interruption of CD40/CD40L rescues Aβ deposition and tau hyper-phosphorylation in an AD animal model. Based on these reports, we can conclude that reduction of CD40 expression by hUCB-MNC administration must be involved in a therapeutic effect in the AD model. As reported previously, CD40 expression was presently also downregulated by hUCB-MSC transplantation, compared with the control groups (Supplementary Figure S5a). Interestingly, we presently observed that exposure to recombinant ICAM-1 reduced CD40 expression in BV2 cells in vitro.
a time-dependent manner (Supplementary Figure S5b). From this result, we propose that sICAM-1 may also be a soluble factor to modulate CD40/CD40L activity.

As CD45, a tyrosine phosphatase (PTP), is a negative regulator of CD40L-induced microglial activation,32,33 To determine CD45 expression in hUCB-MSC injected groups, we also examined the expression of CD45 by western blot analysis. Although there is no significant difference in CD45 expression level between groups, we found a trend toward slight increase (by 20%) in hUCB-MSC-transplanted mice as compared with controls (Supplementary Figure S5a). However, BV2 cells exposed to recombinant ICAM-1 did not show change of CD45 expression level (Supplementary Figure S5b). Collectively, the data are consistent with the suggestion that hUCB-MSC-derived sICAM-1 can improve microglia function for Aβ clearance through recovery of NEP expression and disruption of CD40/CD40L activity.

Although hUCB-MSC was injected into only the hippocampus, Aβ plaques in other areas such as the remote cortex were also reduced (Figure 7). In our previous reports, hUCB-MSC migration toward IL-8 was too strong, because the injected hUCB-MSCs migrated toward the opposite hemispheres in the glioma region of nude mice at 7 days. Moreover, overexpression of the IL-8 receptor CXC chemokine receptor-1 (CXCR1) on hUCB-MSCs enhances cell migration in human glioma-bearing nude mice.19 Detection of hUCB-MSCs expressing ICAM-1 in other areas of the brain could be due to active migration of hUCB-MSCs to Aβ-exposed microglia secreting inflammatory cytokines (Figure 8).

Based on our data, we received clearance last year from the Korea Food and Drug Administration (KFDA) for a phase-I clinical trial of AD (ClinicalTrials.gov Identifier: NCT01297218). We are now performing trials of administration of hUCB-MSCs in the brain parenchyma of AD patients. We suggest that, after considering relevant findings in total, hUCB-MSCs will constitute a new source of stem cell therapy against Aβ plaques in clinical trials.

Materials and Methods
Preparation of hUCB-MSCs and BV2 cells. This study was approved by the Institutional Review Board of MEDIPOST Co. Ltd. Umbilical cord blood was collected from umbilical veins after neonatal delivery, with informed consent from pregnant mothers. hUCB-MSCs were isolated and expanded according to the procedure specified in a previous report.18 To isolate and expand MSCs from cord blood, MNCs were removed by using a Ficoll–Hypaque solution (d = 1.077 g/cm³; Sigma-Aldrich Co., St Louis, MO, USA) and cells were then seeded at 5 × 10³ cells/cm² in culture flasks. After colonies of spindle-shaped cells formed, the cells were reseeded for expansion. Hs68 cells (CRL-1635; ATCC, Rockville, MD, USA), which were used as control, were cultured under identical culture conditions as the hUCB-MSCs. hUCB-MSCs (8 × 10⁶ cells/cm²) were co-cultured in the upper chamber of a Transwell device (BD Biosciences, Franklin Lakes, NJ, USA) (pore size, 1 μm) with Aβ42-exposed rat primary neuronal cells or BV2 cells. BV2 mouse microglia cells were provided by Prof. Inhee-Mook Jung (Seoul National University).

Rat primary neuronal cultures. All animal procedures were conducted in accordance with institutional guidelines according to approved protocols. Pregnant Sprague–Dawley rats were purchased from OrientBio Inc. (Kyonggi, Korea). Brain tissue was dissected from embryonic day 14 rat cortex and hippocampus, and cells were mechanically dissociated in Ca²⁺/Mg²⁺-free Hank’s balanced salt solution. Cells were allowed to proliferate in the presence of 20 ng/ml basic fibroblast growth factor (bFGF) in serum-free neurobasal media. Cell proliferation was maintained in bFGF for 4 days to reach 80% confluence prior to induction of differentiation by withdrawal of the mitogen. Rat primary neuronal cultures were treated with Aβ42 (Sigma-Aldrich) for 12 or 24 h. To induce neurotoxicity, Aβ42 aggregation was performed as described previously.34 Briefly, for the Aβ42 oligomer, peptide was first resuspended in dimethylsulfoxide (MeSO) to 5 mM and then in culture media to achieve a final peptide concentration of 100 μM. Peptide suspensions were incubated at 4°C for 24 h.

Western blot and ELISA. Cell extracts and tissues were prepared by ultrasonication (Branson Ultrasonics Corporation, Danbury, CT, USA) in buffer containing 9.8 M urea, 4% CHAPS, 130 mM dithiothreitol, 40 mM Tris-HCl, and 0.1% sodium dodecyl sulfate (SDS). Protein amount was measured by Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA). Protein extract (20 μg) was separated by SDS-PAGE and the resolved proteins were transferred to nitrocellulose membranes. In order to detect Aβ42 in brain extracts, NuPAGE 12% Bis-Tris gels (Invitrogen, Carlsbad, CA, USA) were used to separate low-molecular-weight proteins by SDS-PAGE. Each membrane was incubated with anti-NEP (R&D Systems, Minneapolis, MN, USA), anti-IDE (Calbiochem, San Diego, CA, USA), and anti-Aβ42 (Novus Biologicals, LLC, Littleton, CO, USA). ELISA was performed according to the manufacturer’s instructions. An ICAM-1 ELISA kit (R&D Systems) and kits for Aβ40 or Aβ42 (Wako Pure Chemical Industries Ltd, Osaka, Japan) were used. For analysis of soluble and insoluble Aβ40 and 42, brain tissues were sonicated in ice-cold PBS containing 1% Triton X-100, 20 mM Tris, 150 mM NaCl, 1 mM EDTA, and a protease/phosphatase inhibitor cocktail. After centrifugation at 13,000 r.p.m. for 15 min at 4°C, the supernatant was analyzed as a soluble fraction and the pellet was resolubilized in 5 M guanidine buffer.29

IHC and thioflavin-S staining. For IHC of mouse brain, mice were killed after hUCB-MSC transplantation. After transplantation, the animals immediately underwent cardiac perfusion with 4% paraformaldehyde in PBS. After perfusion, post-fixation was performed overnight at 4°C, and the brains were then incubated again in 30% sucrose at 4°C until they were equilibrated. Sequential 16-μm coronal cryosections were obtained on a CM1850UV cryostat microtome (Leica Microsystems Inc., Jena, Germany) and stored at −20°C. Tissues or cells were stained with antibodies for MAP2 (Millipore, Billerica, MA, USA), tubulin-JIII (Sigma-Aldrich), human nuclei (Millipore), human β2-microglobulin, Aβ (Abcam, Cambridge, MA, USA), or CD11b (AbD Serotec, Kidlington, UK). Fluorescein isothiocyanate-labeled secondary antibodies (Jackson Immuno-Research Laboratories, Bar Harbor, MN, USA) or the VECTASTAIN Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA) were used and photographed using a confocal microscope (Nikon Corporation, Tokyo, Japan). For thioflavin-S staining, tissues were placed in 1% thioflavin-S solution (Sigma-Aldrich) and then differentiated in 70% ethanol. Aβ plaques were examined by quantitative image analysis using the Metamorph 7.1.2 software (Molecular Devices, Sunnyvale, CA, USA).
siRNA treatment. siRNAs for NEP, LFA-1, and ICAM-1 were purchased from Bioneer Corporation (Daejeon, Korea). BV2 cells and hUCB-MSCs were treated with NEP siRNA and ICAM-1 siRNA, respectively, for 8–14 h using the Lipofectamine 2000 reagent (Invitrogen). These cells were cultured in complete media overnight and co-cultured with hUCB-MSCs or BV2 cells.

Administration of hUCB-MSCs in mice. Double transgenic mice, MoHu APPswe PS1dE9: APP/PS1 were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and offspring mice were produced, selected and maintained according to the protocols recommended by Jackson Laboratory. Ten-month-old APP/PS1 mice or their B6C3 littersmates were anesthetized with ketamine/xylazine intraperitoneally and fixed in a stereotaxic apparatus (Stoeling, Wood Dale, IL, USA) for hUCB-MSC transplantation. Bilateral injections were performed by injecting 3 μl of the cell suspension (1 × 10^6 cells per hippocampus) or recombinant ICAM-1 protein into the dentate gyrus of the hippocampus, or 15 μl of the supernatant into the cisterna magna. hUCB-MSCs were stereotactically inoculated into the hippocampal area (AP: −2.3, L: ±1.3, DV: −2.0 referenced to the bregma) or the cisterna magna with a sterile Hamilton syringe fitted with a 26-gauge needle (Hamilton Company, Reno, NV, USA), using a microinfection pump (KD Scientific, Holliston, MA, USA) in a stereotaxic apparatus. The cell suspension was delivered at a rate of 0.5 μl/min.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A110445).

Reduction of Aβ plaques by siCAM-1 of hUCB-MSC

J-Y Kim et al

Supplementary Information accompanies the paper on Cell Death and Differentiation website (http://www.nature.com/cdd)